Jingze Biotech's Hong Kong IPO Prospectus Expires on June 30

According to Zhitong Finance, Jingze Biotech (Hefei) Pharmaceutical Co., Ltd. submitted its Hong Kong IPO prospectus on December 31, 2025, which will expire on June 30, 2026. China International Capital Corporation and Guoyuan International serve as joint sponsors.

Based on the prospectus, Jingze Biotech is a biopharmaceutical company focused on assisted reproduction and ophthalmology drugs. The company has two core products: JZB30, a recombinant human follicle-stimulating hormone injection for fertility treatment and male hypogonadism, and JZB05, an anti-VEGF intravitreal injection candidate for treating neovascular retinal diseases including wet AMD and diabetic macular edema. As of December 21, 2025, the company has eight candidate drugs in its pipeline, with three in late-stage development.